EA201492148A1 - Способ лечения немелкоклеточного рака легких - Google Patents

Способ лечения немелкоклеточного рака легких

Info

Publication number
EA201492148A1
EA201492148A1 EA201492148A EA201492148A EA201492148A1 EA 201492148 A1 EA201492148 A1 EA 201492148A1 EA 201492148 A EA201492148 A EA 201492148A EA 201492148 A EA201492148 A EA 201492148A EA 201492148 A1 EA201492148 A1 EA 201492148A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lung cancer
cell lung
patient
inoperable
nucleotides
Prior art date
Application number
EA201492148A
Other languages
English (en)
Russian (ru)
Inventor
Чен Дуксин
Шоши Тесслер
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201492148A1 publication Critical patent/EA201492148A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201492148A 2012-05-18 2013-05-17 Способ лечения немелкоклеточного рака легких EA201492148A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18
PCT/US2013/041652 WO2013173757A1 (en) 2012-05-18 2013-05-17 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
EA201492148A1 true EA201492148A1 (ru) 2015-04-30

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492148A EA201492148A1 (ru) 2012-05-18 2013-05-17 Способ лечения немелкоклеточного рака легких

Country Status (17)

Country Link
US (1) US20130310440A1 (https=)
EP (1) EP2849761A1 (https=)
JP (1) JP2015522542A (https=)
KR (1) KR20150024843A (https=)
CN (1) CN104684564A (https=)
AR (1) AR091090A1 (https=)
AU (1) AU2013262589A1 (https=)
BR (1) BR112014028787A2 (https=)
CA (1) CA2874092A1 (https=)
EA (1) EA201492148A1 (https=)
IL (1) IL235459A0 (https=)
IN (1) IN2014DN10390A (https=)
PH (1) PH12014502569A1 (https=)
SG (1) SG11201407649RA (https=)
TW (1) TW201402132A (https=)
UY (1) UY34812A (https=)
WO (1) WO2013173757A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4785252B2 (ja) 1999-02-26 2011-10-05 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Ｔｒｐｍ−２アンチセンス療法
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
PT4122383T (pt) 2010-05-08 2025-05-02 Univ California Aparelho de deteção de scanner sem para a deteção precoce de úlceras
SG192957A1 (en) 2011-03-15 2013-09-30 Univ British Columbia Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
AU2016250527B2 (en) 2015-04-24 2021-01-14 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
MY194948A (en) * 2016-05-13 2022-12-28 Golden Biotechnology Corp Methods and compositions for treating advanced stage non-small cell lung cancer
EP4241670B1 (en) 2017-02-03 2025-12-10 BBI Medical Innovations, LLC Measurement of tissue viability
KR102304070B1 (ko) 2017-02-03 2021-09-23 브루인 바이오메트릭스, 엘엘씨 부종의 측정
US20180220954A1 (en) 2017-02-03 2018-08-09 Bruin Biometrics, Llc Measurement of susceptibility to diabetic foot ulcers
CN116473517A (zh) * 2017-11-16 2023-07-25 布鲁恩生物有限责任公司 使用表皮下水分值对压力性溃疡进行战略治疗
WO2019136287A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria
PL3749181T3 (pl) 2018-02-09 2024-06-10 Bruin Biometrics, Llc Wykrywanie uszkodzenia tkanek
GB2591899B (en) 2018-10-11 2022-03-09 Bruin Biometrics Llc Device with disposable element
WO2022169850A1 (en) 2021-02-03 2022-08-11 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
CN102224419A (zh) * 2008-06-18 2011-10-19 雅培制药有限公司 PlGF-1搭配诊断法和产物
WO2012156817A2 (en) * 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
TW201402132A (zh) 2014-01-16
IL235459A0 (en) 2014-12-31
IN2014DN10390A (https=) 2015-08-14
AU2013262589A1 (en) 2015-01-22
KR20150024843A (ko) 2015-03-09
WO2013173757A1 (en) 2013-11-21
AR091090A1 (es) 2014-12-30
EP2849761A1 (en) 2015-03-25
WO2013173757A8 (en) 2015-04-30
CA2874092A1 (en) 2013-11-21
SG11201407649RA (en) 2014-12-30
US20130310440A1 (en) 2013-11-21
CN104684564A (zh) 2015-06-03
PH12014502569A1 (en) 2015-01-21
JP2015522542A (ja) 2015-08-06
UY34812A (es) 2013-12-31
BR112014028787A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
EA201492148A1 (ru) Способ лечения немелкоклеточного рака легких
MX2013013384A (es) Metodo para tratamiento de cancer de pulmon de celulas no pequeñas.
MX359548B (es) Agentes de iarn modificados.
BR112013005872A2 (pt) compostos, composição farmacêutica e respectivos usos
RU2014101547A (ru) Апоптоз-индуцирующее средство
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
MX2013009191A (es) Oligonucleotidos antisentido.
RU2019130513A (ru) Антисмысловые нуклеиновые кислоты
EA201790420A1 (ru) Средства, представляющие собой модифицированную двухнитевую рнк
BR112015009559A2 (pt) uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
PH12014500865A1 (en) Compounds and methods for enhancing innate immune responses
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
WO2012149546A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
EA201171415A1 (ru) Ингибиторы белков семейства iap
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
BR112015010396A2 (pt) terapia de combinação
JP2014521342A5 (https=)
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
WO2015032800A3 (en) Compositions and methods for inducing senescence in cancer cells
BR112013006541A2 (pt) agente preventivo ou terapêutico para fibrose
WO2012078648A3 (en) Novel method of cancer diagnosis and prognosis and prediction of response to therapy
CL2007001857A1 (es) Compuestos derivados del acido fenil-acetico, inhibidores de cox-2; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, osteoartritis, dolor, entre otras.
WO2011087343A3 (ko) Ｈｐｖ 감염과 관련된 암의 치료용 조성물